AbolerIS Pharma

/ 1 Rue Gaston Veil
44000 Nantes
FR
AbolerIS Pharma
Foundation date
28/11/2019
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.
Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.
IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.
Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.
Upcoming events
All events-
2211 '21
Translational Immunology
Event by: VIB -
2309 '21
Genome Engineering and Synthetic Biology (4th edition)
Event by: VIB -
2909 '21
BIOSPAIN 2021
Event by: ASEBIO, the Spanish Bioindustry Association